P. Chavatte

发表

Comparative Molecular Field Analysis of Selective Cyclooxygenase‐2 (COX‐2) Inhibitors

D. Lesieur, C. Marot, P. Chavatte, 2000 .

Docking study: PPARs interaction with the selected alternative plasticizers to di(2-ethylhexyl) phthalate

P. Chavatte, M. Luyckx, N. Kambia, 2015, Journal of enzyme inhibition and medicinal chemistry.

Toward the Discovery of a Novel Class of YAP–TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP–TEAD Protein–Protein Interface

G. Huet, X. Thuru, P. Chavatte, 2018, Cancers.

4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.

P. Chavatte, P. Desreumaux, M. Djouina, 2010, Journal of medicinal chemistry.

Development and validation of a reversed‐phase HPLC method for the quantification of paclitaxel in different PLGA nanocarriers

P. Chavatte, D. Betbeder, E. Lipka, 2017, Electrophoresis.

Lipid-lowering properties of 6-benzoyl-2(3H)-benzothiazolone and structurally related compounds

J. Poupaert, P. Chavatte, S. Yous, 2005, Journal of enzyme inhibition and medicinal chemistry.

2D QSAR Consensus Prediction for High‐Throughput Virtual Screening. An Application to COX‐2 Inhibition Modeling and Screening of the NCI Database.

Luc Morin-Allory, Philippe Chavatte, Jean-Christophe Mozziconacci, 2004 .

Preclinical studies of a specific PPARγ modulator in the control of skin inflammation.

E. Camera, M. Picardo, P. Chavatte, 2014, The Journal of investigative dermatology.

Three-Dimensional Quantitative Structure–Activity Relationship of MT3 Melatonin Binding Site Ligands: A Comparative Molecular Field Analysis

J. Boutin, P. Renard, P. Chavatte, 2007 .

Antioxydant activity of β-carboline derivatives in the LDL oxidation model.

P. Chavatte, S. Dilly, S. Yous, 2011, European journal of medicinal chemistry.

Polycyclic nitrogen heterocycles as potential thymidine phosphorylase inhibitors: synthesis, biological evaluation, and molecular docking study

M. Sari, P. Chavatte, A. Farce, 2021, Journal of enzyme inhibition and medicinal chemistry.

Intestinal antiinﬂammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor- (cid:1)

J. Auwerx, W. Wahli, P. Chavatte, 2005 .

Development of novel oxazolo[5,4-d]pyrimidines as competitive CB2 neutral antagonists based on scaffold hopping.

P. Chavatte, J. Spencer, X. Dezitter, 2018, European journal of medicinal chemistry.

Scaffold hopping strategy toward original pyrazolines as selective CB₂ receptor ligands.

P. Chavatte, V. Levacher, R. Millet, 2012, European journal of medicinal chemistry.

Docking Study of Ligands into the Colchicine Binding Site of Tubulin

D. Lesieur, P. Chavatte, A. Farce, 2004, Journal of enzyme inhibition and medicinal chemistry.

1080 Preclinical and Toxicological Assessments of the Novel Orally Bioavailable PPAR Ligand GED-0507-34-Levo for the Treatment of Inflammatory Bowel Disease

P. Chavatte, P. Desreumaux, J. Colombel, 2010 .

Conformation of the tripeptide Cbz‐Pro‐Leu‐Trp‐OBzl(CF3)2 deduced from two‐dimensional 1H‐NMR and conformational energy calculations is related to its affinity for NK1‐receptor

P. Chavatte, J. Goossens, L. Goossens, 2001, Journal of peptide science : an official publication of the European Peptide Society.

Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.

P. Chavatte, P. Desreumaux, M. Djouina, 2014, Bioorganic & medicinal chemistry letters.

3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.

P. Chavatte, A. Lemoine, P. Desreumaux, 2013, Bioorganic & medicinal chemistry.

4-Oxo-1,4-dihydropyridines as selective CB₂ cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.

P. Chavatte, P. Desreumaux, M. Djouina, 2012, Journal of medicinal chemistry.

Switching invariant natural killer T (iNKT) cell response from anticancerous to anti-inflammatory effect: molecular bases.

P. Chavatte, B. Bertin, P. Desreumaux, 2014, Journal of medicinal chemistry.

Novel benzopyridothiadiazepines as potential active antitumor agents.

P. Renard, B. Pfeiffer, P. Chavatte, 2005, Journal of medicinal chemistry.

Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands.

J. Boutin, P. Renard, P. Chavatte, 2010, Bioorganic & medicinal chemistry.

Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.

J. Boutin, D. Lesieur, P. Renard, 2008, Bioorganic & medicinal chemistry.

GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis

P. Spagnolo, P. Chavatte, P. Desreumaux, 2020, Cellular & Molecular Immunology.

Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands.

J. Boutin, D. Lesieur, P. Renard, 2003, Journal of medicinal chemistry.

PPARgamma as a new therapeutic target in inflammatory bowel diseases.

X. Thuru, M. Chamaillard, P. Chavatte, 2006, Gut.

New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis.

P. Chavatte, P. Desreumaux, M. Djouina, 2011, Bioorganic & medicinal chemistry.

Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.

D. Lesieur, C. Marot, P. Chavatte, 2001, Journal of medicinal chemistry.

Bis-tetrahydroisoquinoline derivatives: AG525E1, a new step in the search for non-quaternary non-peptidic small conductance Ca(2+)-activated K(+) channel blockers.

J. Wouters, P. Chavatte, Cédric Lamy, 2008, Bioorganic & medicinal chemistry letters.

Microwave-mediated synthesis and manipulation of a 2-substituted-5-aminooxazole-4-carbonitrile library

J. Deadman, P. Chavatte, Jahangir Amin, 2012 .

Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.

P. Depreux, P. Chavatte, A. Lemoine, 2012, Journal of medicinal chemistry.

Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines.

L. Buée, P. Chavatte, D. Blum, 2015, European journal of medicinal chemistry.

Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARgamma agonists.

J. Boutin, D. Lesieur, P. Renard, 2006, Bioorganic & medicinal chemistry.

Quantitative structure-activity relationships studies of antioxidant hexahydropyridoindoles and flavonoid derivatives

P. Chavatte, A. Farce, S. Dilly, 2007, Journal of enzyme inhibition and medicinal chemistry.

Relationships between Th1 or Th2 iNKT Cell Activity and Structures of CD1d-Antigen Complexes: Meta-analysis of CD1d-Glycolipids Dynamics Simulations

Philippe Chavatte, Eric Henon, Xavier Laurent, 2014, PLoS Comput. Biol..

NMR studies of interactions of new CB2 cannabinoid receptor ligands with cyclodextrins hosts. Correlation with micellar electrokinetic chromatography and reversed phase high performance liquid chromatography

P. Chavatte, A. Farce, C. Vaccher, 2014, Journal of Inclusion Phenomena and Macrocyclic Chemistry.

Potent and selective farnesyl transferase inhibitors.

P. Chavatte, J. Goossens, N. Pommery, 2004, Journal of medicinal chemistry.

PPARγ as a new therapeutic target in inflammatory bowel diseases

Philippe Chavatte, Pierre Desreumaux, X. Thuru, 2006, Gut.

Exploring chiral separation of 3-carboxamido-5-aryl isoxazole derivatives by supercritical fluid chromatography on amylose and cellulose tris dimethyl- and chloromethyl phenylcarbamate polysaccharide based stationary phases.

P. Chavatte, C. Vaccher, Alina Ghinet, 2016, Journal of chromatography. A.

Investigations of new lead structures for the design of novel cyclooxygenase-2 inhibitors.

Philippe Chavatte, Michel Luyckx, P. Chavatte, 2002, European journal of medicinal chemistry.

Design, Synthesis and In Vitro Evaluation of Novel Derivatives as Serotonin N -Acetyltransferase Inhibitors

G. Ferry, J. Boutin, P. Chavatte, 2002, Journal of enzyme inhibition and medicinal chemistry.

Synthesis and biological evaluation of conformationally restricted derivatives of tryptophan as NK1/NK2 ligands

P. Chavatte, J. Goossens, R. Houssin, 1999, Letters in Peptide Science.

Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer.

P. Chavatte, A. Lemoine, A. Farce, 2011, Journal of medicinal chemistry.

Solid-phase synthesis and pharmacological evaluation of a library of peptidomimetics as potential farnesyltransferase inhibitors: an approach to new lead compounds.

P. Chavatte, A. Lemoine, A. Farce, 2006, European journal of medicinal chemistry.

Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.

Philippe Chavatte, Pierre Desreumaux, Nicolas Renault, 2012, Journal of medicinal chemistry.

Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.

Philippe Chavatte, Amaury Farce, P. Depreux, 2006, Journal of medicinal chemistry.

Design, synthesis, and pharmacological evaluation of new farnesyl protein transferase inhibitors.

P. Chavatte, J. Goossens, J. Pommery, 2002, Journal of medicinal chemistry.

Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands.

J. Nicolas, J. Boutin, D. Lesieur, 2002, Journal of medicinal chemistry.

Differences in Binding Sites of Two Melatonin Receptors Help to Explain Their Selectivity to Some Melatonin Analogs: A Molecular Modeling Study

P. Chavatte, R. Efremov, A. Farce, 2006, Journal of biomolecular structure & dynamics.

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ

J. Auwerx, W. Wahli, D. Metzger, 2005, The Journal of experimental medicine.

Enantioseparation of pyroglutamide derivatives on polysaccharide based chiral stationary phases by high-performance liquid chromatography and supercritical fluid chromatography: a comparative study.

Philippe Chavatte, P. Chavatte, C. Vaccher, 2014, Journal of chromatography. A.

Structural Insight into PPAR? Ligands Binding

P. Chavatte, A. Farce, N. Renault, 2009 .

2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database

Luc Morin-Allory, Philippe Chavatte, Jean-Christophe Mozziconacci, 2004, J. Chem. Inf. Model..

Characterisation of novel defective thiopurine S-methyltransferase allelic variants.

M. Loriot, P. Chavatte, J. Lo-Guidice, 2008, Biochemical pharmacology.

Conformational analysis of tripeptide Ac‐Lys‐Pro‐Val‐NH2, COOH‐terminal sequence of alpha‐MSH

D. Lesieur, P. Chavatte, S. Yous, 2001, The Journal of pharmacy and pharmacology.

Synthesis of 2,3 and 4,5-Dihydro-hydroxy-isoxazoles and Isoxazoles Under Different pH Conditions

P. Chavatte, C. Vaccher, J. Bonte, 2010 .

Homology modeling of MT1 and MT2 receptors.

G. Vergoten, D. Lesieur, P. Chavatte, 2008, European journal of medicinal chemistry.

Pharmacophoric search and 3D-QSAR comparative molecular field analysis studies on agonists of melatonin sheep receptors.

L Morin-Allory, D. Lesieur, P. Renard, 1998, Journal of medicinal chemistry.

Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.

P. Chavatte, J. Spencer, Supojjanee Sansook, 2017, Journal of medicinal chemistry.

Therapeutical potential of CB₂ receptors in immune-related diseases.

P. Chavatte, P. Desreumaux, R. Millet, 2013, Current molecular pharmacology.

Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.

P. Chavatte, P. Desreumaux, M. Djouina, 2015, ACS medicinal chemistry letters.

Virtual Screening of CB2 Receptor Agonists from Bayesian Network and High‐Throughput Docking: Structural Insights into Agonist‐Modulated GPCR Features

Philippe Chavatte, Pierre Desreumaux, Xavier Laurent, 2013, Chemical biology & drug design.

Homology Modeling of 5-HT2C Receptors

Philippe Chavatte, Nicolas Renault, Amaury Farce, 2011 .

Design, synthesis and biological evaluation of potent FAAH inhibitors.

P. Chavatte, N. Renault, R. Millet, 2016, Bioorganic & medicinal chemistry letters.

2,6-Diphenylthiazolo[3,2-b][1,2,4]triazoles as telomeric G-quadruplex stabilizers.

P. Chavatte, J. Mergny, P. Roussel, 2009, Bioorganic & medicinal chemistry letters.

SINAPs: A Software Tool for Analysis and Visualization of Interaction Networks of Molecular Dynamics Simulations

P. Chavatte, A. Farce, A. Lachgar, 2022, J. Chem. Inf. Model..

Novel structural insights for drug design of selective 5-HT(2C) inverse agonists from a ligand-biased receptor model.

P. Chavatte, A. Farce, N. Renault, 2010, European journal of medicinal chemistry.

Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents.

P. Chavatte, P. Desreumaux, M. Body-Malapel, 2012, Current medicinal chemistry.

Importance of the second extracellular loop for melatonin MT1 receptor function and absence of melatonin binding in GPR50

P. Chavatte, E. Cecon, P. Delagrange, 2018, British journal of pharmacology.

GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro

P. Spagnolo, P. Chavatte, P. Desreumaux, 2021, PloS one.

PPARc AS A NEW THERAPEUTIC TARGET IN INFLAMMATORY BOWEL DISEASES

X. Thuru, M. Chamaillard, P. Chavatte, 2006 .

NMR study of five N-terminal peptide fragments of the vasoactive intestinal peptide: crucial role of aromatic residues.

P. Chavatte, J. Goossens, J. Hénichart, 1996, Peptide research.

Molecular modelling of phthalates – PPARs interactions

P. Chavatte, M. Luyckx, N. Kambia, 2008, Journal of enzyme inhibition and medicinal chemistry.

MOLECULAR MODELING OF HUMAN MT 1 AND MT 2 MELATONIN RECEPTORS

P. Chavatte, R. Efremov, A. Chugunov, 2006 .

Chlorinated and brominated bisphenol A derivatives: Synthesis, characterization and determination in water samples.

P. Chavatte, V. Migeot, A. Farce, 2018, Chemosphere.

Identification of a pharmacophore of SKCa channel blockers

P. Chavatte, A. Farce, S. Dilly, 2005, Journal of enzyme inhibition and medicinal chemistry.

Structural insight into PPARgamma ligands binding.

P. Chavatte, A. Farce, N. Renault, 2009, Current Medicinal Chemistry.

Genetic polymorphism of CYP4A11 and CYP4A22 genes and in silico insights from comparative 3D modelling in a French population.

P. Chavatte, C. L. Lino Cardenas, J. Lo-Guidice, 2011, Gene.

PPARγ as a new therapeutic target in inflammatory bowel diseases

X. Thuru, M. Chamaillard, P. Chavatte, 2006, Gut.

[Melatonin, a pertinent prototype for therapeutic innovation].

D. Lesieur, P. Renard, C. Marot, 1998, Therapie.